β¨ Medicines Consent Notices
1016
NEW ZEALAND GAZETTE
No. 46
Product: Vergo 16
Active Ingredient(s): Bethahistine dihydrochloride 16mg
Dosage Form: Tablet
New Zealand Sponsor: Pacific Pharmaceuticals Limited
Manufacturer(s): Gerard Laboratories, Dublin, Eire
Product: Vicks Sinex 12 Hour Nasal Spray
Active Ingredient(s): Oxymetazoline hydrochloride 0.05%w/v
Dosage Form: Nasal spray solution
New Zealand Sponsor: Procter & Gamble NPD Inc
Manufacturer(s): Olay Company Inc., Barrio Rio Llano, Cayey, Puerto Rico
Product: Vicks Sinex 12 Hour Ultra Fine Mist
Active Ingredient(s): Oxymetazoline hydrochloride 0.05%w/v
Dosage Form: Nasal spray solution
New Zealand Sponsor: Procter & Gamble NPD Inc
Manufacturer(s): Olay Company Inc., Barrio Rio Llano, Cayey, Puerto Rico
Dated this 27th day of April 2000.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go3045
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the schedule hereto:
Schedule
Product: Codalax Forte
Active Ingredient(s): Poloxamers 200mg/mL
Danthron 15mg/mL
Dosage Form: Oral suspension
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer(s): Douglas Manufacturing, div. Douglas Pharmaceuticals Limited, Lincoln, Auckland
Regent Laboratories Limited, North Acton, London, England
Universal Products Limited, Lytham, Lancashire, England
Condition: This medicine may only be used for the prevention or treatment of constipation in the terminally ill.
Note: This consent is valid for 2 years from 30 July 2000.
Product: Codalax
Active Ingredient(s): Poloxamers 40mg/mL
Danthron 5mg/mL
Dosage Form: Oral suspension
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer(s): Douglas Manufacturing, div. Douglas Pharmaceuticals Limited, Lincoln, Auckland
Regent Laboratories Limited, North Acton, London, England
Universal Products Limited, Lytham, Lancashire, England
Condition: This medicine may only be used for the prevention or treatment of constipation in the terminally ill.
Note: This consent is valid for 2 years from 30 July 2000.
Product: Invirase
Active Ingredient(s): Saquinavir mesylate 228.7mg equivalent to 200mg Saquinavir free base
Dosage Form: Capsule
New Zealand Sponsor: Roche Products (New Zealand) Limited
Manufacturer(s): F Hoffmann-La Roche AG, Basle, Switzerland
Hoffmann-La Roche Inc, Nutley, New Jersey, United States of America
Note: This consent is valid for 2 years from 6 June 2000.
Dated this 27th day of April 2000.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go3044
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2000, No 46
Gazette.govt.nz —
NZ Gazette 2000, No 46
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of New Medicines under the Medicines Act 1981
(continued from previous page)
π₯ Health & Social Welfare27 April 2000
Medicines, Consent, Distribution, Health, Bethahistine dihydrochloride, Oxymetazoline hydrochloride
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Renewal of Provisional Consent to the Distribution of New Medicines
π₯ Health & Social Welfare27 April 2000
Medicines, Provisional Consent, Distribution, Health, Poloxamers, Danthron, Saquinavir mesylate
- G. R. Boyd, Chief Advisor, Safety and Regulation